RxDoctor Payments Data

Penelope Harris, MD

Hematology & Oncology · Bolivar, MONPI 1154389260

Payments from drug & device makers

$23,487in general payments, 2019–2025

Across 703 payments — averaging $33.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rigel Pharmaceuticals, Inc.$9K
  • Novartis$4K
  • Bristol Myers Squibb$995
  • AstraZeneca$777
  • Merck$706
  • AbbVie$650
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$12,43497%
  • Education$4033%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Rigel Pharmaceuticals, Inc.23$8,661
Novartis81$3,559
Bristol Myers Squibb71$995
AstraZeneca41$777
Merck36$706
AbbVie29$650
Johnson & Johnson30$631
Gilead(2 entities)33$564
E.r. Squibb & Sons, L.L.C.34$542
Genentech USA, Inc.35$443
Seagen Inc.14$415
Pfizer26$348
Karyopharm Therapeutics Inc.3$329
Lilly USA, LLC17$314
Daiichi Sankyo Inc.13$279
Eisai Inc.15$275
Incyte Corporation15$257
Exelixis Inc.12$236
Sanofi11$231
Bayer10$219
Jazz Pharmaceuticals Inc.8$209
Regeneron Healthcare Solutions, Inc.9$204
GSK11$203
Takeda Pharmaceuticals U.S.A., Inc.7$175
Agios Pharmaceuticals, Inc.2$161
Amgen9$159
Stemline Therapeutics Inc.9$150
G1 Therapeutics, Inc.6$106
Boehringer Ingelheim4$104
Dendreon Pharmaceuticals LLC5$99
Array Biopharma Inc7$98
Beigene USA, Inc.5$93
Pharmacyclics LLC, An Abbvie Company5$92
Puma Biotechnology, Inc.5$88
Mirati Therapeutics, Inc.5$81
Apellis Pharmaceuticals, Inc.4$77
Sobi, Inc4$72
Kyowa Kirin, Inc.4$65
Pharmaessentia USA Corporation3$61
Mylan Institutional Inc.3$58
Pharmacosmos Therapeutics Inc.3$58
Springworks Therapeutics, Inc.3$54
Ipsen Biopharmaceuticals, Inc3$52
Sun Pharmaceutical Industries Inc.2$42
Genmab U.S., Inc.2$41
Astellas Pharma US Inc2$39
Servier Pharmaceuticals LLC2$39
Foundation Medicine, Inc.2$36
Taiho Oncology, Inc.2$35
AVEO Pharmaceuticals, Inc.2$26
Acrotech Biopharma Inc.2$26
Caris MPI, Inc.1$25
Tersera Therapeutics LLC1$23
Adaptive Biotechnologies Corporation1$20
Sumitomo Pharma America, Inc.1$20
Corcept Therapeutics1$20
Menarini Silicon Biosystems, Inc.1$19
Beone Medicines USA, Inc.1$18
Epizyme, Inc.1$18
Spectrum Pharmaceuticals Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,487 in reported general payments places this provider in the 65th percentile of 211 hematology & oncology providers in Missouri.

See all hematology & oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$1,522,171
Medicare patients
268
Services billed
64,338

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate21$343,473
ImbruvicaIbrutinib13$212,243
KisqaliRibociclib Succinate14$155,362
BrukinsaZanubrutinib11$127,466
EliquisApixaban95$88,450
XareltoRivaroxaban18$10,024
Colesevelam Hcl12$3,817
Sucralfate35$2,778
Hydroxyurea59$2,196
Letrozole126$2,022
Levothyroxine Sodium48$1,113
Prochlorperazine Maleate46$1,020
ValacyclovirValacyclovir Hcl28$934
Ibandronate Sodium21$920
Acyclovir20$611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$777$343,47321 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$92$212,24313 claims
NovartisKisqali$3,559$155,36214 claims
Beigene USA, Inc.Brukinsa$93$127,46611 claims
PfizerEliquis$348$88,45095 claims
Johnson & JohnsonXarelto$631$10,02418 claims
Lilly USA, LLCOlanzapine$314$22816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 211 hematology & oncology providers in Missouri.

Other hematology & oncology in Bolivar

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →